Holen Sie sich die Stockscreener-App
5.16
2.64%
-0.14
Handel nachbörslich:
5.16
Schlusskurs vom Vortag:
$5.30
Offen:
$5.24
24-Stunden-Volumen:
492.85K
Relative Volume:
0.34
Marktkapitalisierung:
$143.73M
Einnahmen:
$675.00K
Nettoeinkommen (Verlust:
$-39.95M
KGV:
-2.5092
EPS:
-2.0564
Netto-Cashflow:
$-28.67M
1W Leistung:
-1.99%
1M Leistung:
-0.19%
6M Leistung:
-27.02%
1J Leistung:
+19.44%
1-Tages-Spanne:
$5.12
$5.24
1-Wochen-Bereich:
$5.04
$5.34
52-Wochen-Spanne:
$3.71
$8.74
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Firmenname
Unicycive Therapeutics Inc
Sektor
Branche
Telefon
650-384-0642
Adresse
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW
Compare UNCY vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
5.16 | 151.81M | 675.00K | -39.95M | -28.67M | -2.0564 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Eingeleitet | Guggenheim | Buy |
| 2024-04-04 | Eingeleitet | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Aktie (UNCY) Neueste Nachrichten
Bronstein, Gewirtz & Grossman LLC Urges Unicycive - globenewswire.com
Deadline Soon: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - FinancialContent
Class action lawsuit filed against Unicycive Th... - Pluang
UNCY Stock On Track For Worst Day In About A Year Ahead Of FDA Decision On Lead Drug - Stocktwits
UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time? - Stocktwits
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval - Stocktwits
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
UNCY INVESTOR ALERT: Securities Class Action Filed Against Unicycive Therapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP - Business Wire
UNICYCIVE INVESTOR ALERT: Bragar Eagel & Squire, P.C. - globenewswire.com
DEADLINE ALERT for YSS, HIMS, and UNCY: The Law Offices of - globenewswire.com
UNCY INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Unicycive Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm - lincolnjournal.com
Law Offices of Howard G. Smith Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders To Inquire About Securities Fraud Class Action - FinancialContent
Robbins LLP Informs Investors of the Unicycive Therapeutics, Inc. Securities Class Action - Business Wire
UNCY CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit On Behalf Of Unicycive Therapeutics, Inc. Investors - The Daily Tribune News
Unicycive Therapeutics stock trades near USD 5.26 - AD HOC NEWS
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - azcentral.com and The Arizona Republic
Unicycive Therapeutics (NASDAQ:UNCY) Upgraded at Zacks Research - MarketBeat
Benchmark Co. Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Raises Target Price to $15 - Moomoo
UNCY Maintained by Benchmark -- Price Target Raised to $15.00 - GuruFocus
Benchmark raises Unicycive Therapeutics price target on FDA progress By Investing.com - Investing.com Canada
UNCY Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Noble Financial Has Positive Forecast for UNCY Q3 Earnings - MarketBeat
Research Analysts Set Expectations for UNCY Q3 Earnings - MarketBeat
Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia - Bitget
Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to Hold at Wall Street Zen - MarketBeat
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - TechFinancials
Nantahala Capital (UNCY) discloses 2.81M-share, 9.99% holding in Unicycive - Stock Titan
Unicycive Therapeutics (UNCY): Vivo Opportunity reports 9.99% beneficial ownership stake - Stock Titan
Noble Financial Has Pessimistic View of UNCY Q2 Earnings - MarketBeat
B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating - marketscreener.com
H.C. Wainwright Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Guggenheim cuts Unicycive stock price target to $25 on FDA delays - Investing.com
Unicycive Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.5, Implies 550% Upside - TradingView
Unicycive Therapeutics (NASDAQ:UNCY) Announces Quarterly Earnings Results - MarketBeat
Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.7, Implies 554% Upside - TradingView
Unicycive Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Unicycive Therapeutics Q2 Results: EPS beats estimates by 82% - scanx.trade
Form 8K Unicycive Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Unicycive Reports Q2 2026 Results: $1.7M Net Loss, $61.4M Cash and Runway Into 2027 - TradingView
Unicycive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Unicycive Reports Q2 Loss As FDA Assigns OLC Facility Inspection - Moomoo
Unicycive Therapeutics shares rise after second-quarter loss beats forecasts - Yahoo Finance
Unicycive Therapeutics stock rises 2% on second quarter earnings beat By Investing.com - Investing.com Australia
Unicycive Therapeutics stock rises 2% on second quarter earnings beat - Investing.com
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Unicycive Therapeutics Reports FDA Facility Inspection Assigned for OLC Manufacturing Vendor, Plans NDA Resubmission After Successful Inspection - Quiver Quantitative
Unicycive Reports $61.4M in Cash and Securities as FDA Assigns Inspection - Stock Titan
Unicycive Therapeutics (UNCY) posts $14.5M H1 loss, raises $34M equity - Stock Titan
Unicycive Therapeutics, Inc. Q2 2026: Net income $(1.72M), EPS $(0.06) — 10-Q Summary - TradingView
Finanzdaten der Unicycive Therapeutics Inc-Aktie (UNCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):